Showing 4881-4890 of 9931 results for "".
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- It’s Melanoma Monday! Focus on Preventionhttps://practicaldermatology.com/news/its-melanoma-monday-focus-on-prevention/2460792/With new data showing that one-third of Americans lack a basic understanding of skin cancer and sun protection, the American Academy of Dermatology’s annual Melanoma Monday takes on special significance.
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Health Canada Approves Two New Gynecological Indications For Candela’s CO2RE Laser Platformhttps://practicaldermatology.com/news/health-canada-approves-two-new-gynecological-indications-for-candelas-co2re-laser-platform/2460434/Health Canada has approved Candela’s CO2RE laser for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser, a single CO2 platform equipped w
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,
- BTL Taps Drew Barrymore as First Emsculpt Celebrity Ambassadorhttps://practicaldermatology.com/news/btl-taps-drew-barrymore-as-first-emscuplt-celebrity-ambassador/2460052/Drew Barrymore is Emsculpt's first celebrity ambassador. Through her partnership with Emsculpt, the actress and lifestyle mogul will share her treatment experience and results with media and on her social media channels. Ba